Target intelligence / Profile preview

Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharides (MenACWY polysaccharides)

Target
MenACWY polysaccharides
Molecular classification
Other
01

Overview

Neisseria meningitidis serogroups A, C, Y, and W-135 are encapsulated Gram-negative bacteria responsible for life-threatening invasive diseases such as meningitis and septicemia (StatPearls, 2023). The capsular polysaccharides of these serogroups are essential virulence factors that protect the bacteria from host immune defenses by inhibiting phagocytosis (CDC, 2022). In the context of immunization, these polysaccharides serve as the primary antigens in quadrivalent meningococcal vaccines (FDA, 2020). When introduced into the body, typically conjugated to a carrier protein like diphtheria toxoid or CRM197 to enhance immunogenicity and induce T-cell memory, they stimulate the production of specific bactericidal antibodies (StatPearls, 2023). These antibodies recognize the polysaccharide capsule, leading to the destruction of the bacteria through complement-mediated lysis or opsonophagocytosis, thereby preventing invasive disease (FDA, 2020).

Other names
Meningococcal group A, C, Y, and W-135 capsular polysaccharidesQuadrivalent meningococcal polysaccharidesMenACWY antigensMeningococcal polysaccharide vaccine
02

Mechanism of action

Induction of serogroup-specific bactericidal antibodies that facilitate complement-mediated lysis and opsonophagocytosis of Neisseria meningitidis (FDA, 2020; StatPearls, 2023).

03

Biological functions

Immune responseBacterial virulence
04

Disease associations

InfectionMeningitisSepticemia
05

Safety considerations

Injection site reactions (pain, erythema, swelling) (FDA, 2020)Systemic reactions (fever, headache, fatigue) (CDC, 2022)Syncope (especially in adolescents) (CDC, 2022)Guillain-Barré syndrome (rarely reported post-marketing) (FDA, 2020)
06

Interacting drugs

Menactra

4 more in the full profile.

07

Biomarkers

Serum bactericidal assay (SBA) titers (StatPearls, 2023)Serogroup-specific IgG antibody levels (CDC, 2022)

Beyond the preview

Go deeper on Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharides (MenACWY polysaccharides).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharides (MenACWY polysaccharides).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call